Minerva Surgical - UTRS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $20.00
  • Forecasted Upside: 2,976.92%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.65
+0 (0.00%)

This chart shows the closing price for UTRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Minerva Surgical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UTRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UTRS

Analyst Price Target is $20.00
▲ +2,976.92% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Minerva Surgical in the last 3 months. The average price target is $20.00, with a high forecast of $20.00 and a low forecast of $20.00. The average price target represents a 2,976.92% upside from the last price of $0.65.

This chart shows the closing price for UTRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Minerva Surgical. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2023Piper SandlerLower Target$100.00 ➝ $20.00Low
8/10/2022Piper SandlerLower TargetOverweight$120.00 ➝ $100.00Low
8/10/2022JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightLow
5/12/2022Piper SandlerLower Target$240.00 ➝ $120.00High
3/9/2022Piper SandlerLower TargetOverweight$340.00 ➝ $240.00Low
12/3/2021SVB LeerinkLower TargetOutperform$340.00 ➝ $240.00Low
11/16/2021SVB LeerinkInitiated CoverageOutperform$340.00High
11/16/2021UBS GroupInitiated CoverageBuy$300.00High
11/16/2021JPMorgan Chase & Co.Initiated CoverageOverweight$280.00High
11/16/2021Piper SandlerInitiated CoverageOverweight$340.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Minerva Surgical logo
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Read More

Today's Range

Now: $0.65
Low: $0.65
High: $0.65

50 Day Range

MA: $0.63
Low: $0.52
High: $0.80

52 Week Range

Now: $0.65
Low: $0.33
High: $14.00

Volume

18 shs

Average Volume

1,167 shs

Market Capitalization

$5.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Minerva Surgical?

The following equities research analysts have issued stock ratings on Minerva Surgical in the last year: Piper Sandler.
View the latest analyst ratings for UTRS.

What is the current price target for Minerva Surgical?

1 Wall Street analysts have set twelve-month price targets for Minerva Surgical in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 2,976.9%. Piper Sandler has the highest price target set, predicting UTRS will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $20.00 for Minerva Surgical in the next year.
View the latest price targets for UTRS.

What is the current consensus analyst rating for Minerva Surgical?

Minerva Surgical currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for UTRS.

What other companies compete with Minerva Surgical?

Other companies that are similar to Minerva Surgical include Titan Medical, Avinger, Sharps Technology, Acutus Medical and Assure. Learn More about companies similar to Minerva Surgical.

How do I contact Minerva Surgical's investor relations team?

The company's listed phone number is 855-646-7874 and its investor relations email address is [email protected]. The official website for Minerva Surgical is www.minervasurgical.com. Learn More about contacing Minerva Surgical investor relations.